Immune checkpoint therapy for pancreatic cancer

10.1038/nature07205

10.1126/science.aaf1490

10.1634/theoncologist.2014-0422

10.1080/2162402X.2015.1112942

10.1007/s00262-013-1485-8

10.1056/NEJMra1404198

10.1016/j.ctrv.2013.11.005

10.1038/nature16965

Alegre ML, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, Thompson CB. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996;157:4762-4770.

10.1016/j.bbcan.2014.12.001

Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.

10.1038/nri1349

Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.

10.1111/j.1600-065X.2009.00770.x

10.1126/science.1202947

10.231/JIM.0b013e31824a4d79

10.1146/annurev.iy.11.040193.001203

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3:87-98.

10.1084/jem.20082492

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.

10.1084/jem.20130579

National cancer institute. NCI Drug Dictionary. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov/publications/dictionaries/cancer-drug" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.cancer.gov/publications/dictionaries/cancer-drug</ext-link>.

10.1097/CJI.0b013e3181eec14c

10.1097/CJI.0b013e31829fb7a2

Le D. A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01896869" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT01896869</ext-link>.

Mulcahy M. Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01473940" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT01473940</ext-link>.

10.1093/annonc/mdu205

Duffy AG, Makarova-Rusher OV, Drew Pratt DEK, Alewine C, Fioravanti S, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V. A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. Available from: <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/160088-173" xmlns:xlink="http://www.w3.org/1999/xlink">http://meetinglibrary.asco.org/content/160088-173</ext-link>.

Study of Mogamulizumab MEDI4736 and Mogamulizumab Tremelimumab in Subjects w/ Advanced Solid Tumors. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02301130" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02301130</ext-link>.

O&rsquo;Reilly EM. Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02558894" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02558894</ext-link>.

Duffy AG. Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02311361" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02311361</ext-link>.

O&rsquo;Hara MH. Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02639026" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02639026</ext-link>.

Padmanee S. Study of Tremelimumab in Patients With Advanced Solid Tumors. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02527434" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02527434</ext-link>.

10.1146/annurev.immunol.26.021607.090331

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.

10.1038/nm863

10.1084/jem.20090847

10.1111/cas.12663

10.1038/nm730

10.1038/nature04444

10.1158/0008-5472.can-11-0993

10.1038/nature07662

10.1016/j.coi.2011.12.009

Le DT, Crocenzi TS, Uram JN, Lutz ER, Laheru DA, Sugar EA, Vonderheide RH, Fisher GA, Ko AH, Murphy AL. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Available from: <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/146694-156" xmlns:xlink="http://www.w3.org/1999/xlink">http://meetinglibrary.asco.org/content/146694-156</ext-link>.

Firdaus I, Waterhouse DM, Gutierrez M, Wainberg ZA, George B, Kelly K, Bekaii-Saab TS, Carrizosa DR, Soliman HH, Fraser CD. nab-paclitaxel (nab-P) + nivolumab (Nivo) &plusmn; gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). Available from: <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/159332-173" xmlns:xlink="http://www.w3.org/1999/xlink">http://meetinglibrary.asco.org/content/159332-173</ext-link>.

Zheng L. Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https: //clinicaltrials.gov/ct2/show/study/NCT02451982" xmlns:xlink="http://www.w3.org/1999/xlink">https: //clinicaltrials.gov/ct2/show/study/NCT02451982</ext-link>.

Khemka V. Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (NivoPlus). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02423954" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02423954</ext-link>.

Oft M. A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. Available from: <ext-link ext-link-type="uri" xlink:href="https: //clinicaltrials.gov/ct2/show/NCT02009449" xmlns:xlink="http://www.w3.org/1999/xlink">https: //clinicaltrials.gov/ct2/show/NCT02009449</ext-link>.

Hambleton J. Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers (FPA008-003). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02526017" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02526017</ext-link>.

Wainberg ZA, Eisenberg PD, Sachdev JC, Weise AM, Kaufman DR, Hutchinson M, Tong S, Aromin I, Hu-Lieskovan S, Patnaik A. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. Available from: <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/159443-173" xmlns:xlink="http://www.w3.org/1999/xlink">http://meetinglibrary.asco.org/content/159443-173</ext-link>.

Rahma O. Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02305186" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02305186</ext-link>.

Khemka V, Weiss G. Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02331251" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02331251</ext-link>.

Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers (MK-3475 GI). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02268825" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02268825</ext-link>.

Zheng L. Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02648282" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02648282</ext-link>.

Indamdar S. ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer (KEYNOTE144). Available from: <ext-link ext-link-type="uri" xlink:href="https: //clinicaltrials.gov/ct2/show/NCT02362048" xmlns:xlink="http://www.w3.org/1999/xlink">https: //clinicaltrials.gov/ct2/show/NCT02362048</ext-link>.

Wang-Gillam A. Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02546531" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02546531</ext-link>.

Chung V. Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02432963" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02432963</ext-link>.

Mahalingam D. Study of Pembrolizumab With REOLYSIN&reg; and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02620423" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02620423</ext-link>.

Rosenberg SA. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01174121" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT01174121</ext-link>.

Khleif SN. Gemcitabine and CT-011 for Resected Pancreatic Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01313416" xmlns:xlink="http://www.w3.org/1999/xlink">https://ClinicalTrials.gov/show/NCT01313416</ext-link>.

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01386502" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT01386502</ext-link>.

10.1007/s00268-010-0448-x

10.1038/nri2326

10.1038/70932

10.1016/j.immuni.2007.05.016

10.1073/pnas.192461099

10.1016/j.canlet.2008.03.056

10.1146/annurev.immunol.23.021704.115611

10.1097/CJI.0000000000000062

10.1007/s00262-011-1104-5

10.3892/or.2013.2955

10.1002/ijc.21775

10.1158/1078-0432.CCR-06-2746

Borazanci EH, Hong DS, Gutierrez M, Rasco DW, Reid TR, Veeder MH, Tawashi A, Lin J, Dimery IW. Ibrutinib durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study. Available from: <ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/160089-173" xmlns:xlink="http://www.w3.org/1999/xlink">http://meetinglibrary.asco.org/content/160089-173</ext-link>.

10.1158/0008-5472.CAN-14-2852

J&auml;nne PA. A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02586987" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02586987</ext-link>.

Govindan R. MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02669914" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02669914</ext-link>.

Sun W. Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02583477" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02583477</ext-link>.

10.1056/NEJMoa1200694

10.1007/82_2010_114

10.1158/0008-5472.can-11-2637

10.1084/jem.20100643

10.1007/s00262-011-1155-7

10.1111/j.1600-065X.2009.00768.x

10.1073/pnas.1003345107

Hawkins WG. Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT00732082" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT00732082</ext-link>.

Le DT. GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02243371" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/study/NCT02243371</ext-link>.